🔎 Trials Near Me

Home › Burkitt Lymphoma › Washington

Burkitt Lymphoma clinical trials in Washington

14 studies for Burkitt Lymphoma are looking for participants at sites in Washington.

Cities in Washington

Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)

  • University of Washington Fred Hutchinson Comprehensive Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07936266

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
  • and 1 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT04546399

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Nov 3, 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07097363

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Seattle Children's Hospital, Seattle
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
  • Mary Bridge Children's Hospital and Health Center, Tacoma
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.